These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2123 related articles for article (PubMed ID: 8044834)

  • 21. [Tumor-infiltrating lymphocytes from human metastatic melanoma].
    Itoh K
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2119-26. PubMed ID: 3496855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
    Salgaller ML; Weber JS; Koenig S; Yannelli JR; Rosenberg SA
    Cancer Immunol Immunother; 1994 Aug; 39(2):105-16. PubMed ID: 7519125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts.
    Mackensen A; Veelken H; Lahn M; Wittnebel S; Becker D; Köhler G; Kulmburg P; Brennscheidt U; Rosenthal F; Franke B; Mertelsmann R; Lindemann A
    J Mol Med (Berl); 1997 Apr; 75(4):290-6. PubMed ID: 9151215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.
    Mukherji B; Guha A; Chakraborty NG; Sivanandham M; Nashed AL; Sporn JR; Ergin MT
    J Exp Med; 1989 Jun; 169(6):1961-76. PubMed ID: 2471770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.
    Möller P; Sun Y; Dorbic T; Alijagic S; Makki A; Jurgovsky K; Schroff M; Henz BM; Wittig B; Schadendorf D
    Br J Cancer; 1998 Jun; 77(11):1907-16. PubMed ID: 9667667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines.
    Dufour E; Carcelain G; Gaudin C; Flament C; Avril MF; Faure F
    J Immunol; 1997 Apr; 158(8):3787-95. PubMed ID: 9103444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
    Yang S; Linette GP; Longerich S; Haluska FG
    J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients.
    Mazzocchi A; Belli F; Mascheroni L; Vegetti C; Parmiani G; Anichini A
    Int J Cancer; 1994 Aug; 58(3):330-9. PubMed ID: 8050813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
    Itoh K; Tilden AB; Balch CM
    Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.
    Asai T; Storkus WJ; Whiteside TL
    Clin Diagn Lab Immunol; 2000 Mar; 7(2):145-54. PubMed ID: 10702485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases.
    Slingluff CL; Darrow T; Vervaert C; Quinn-Allen MA; Seigler HF
    J Natl Cancer Inst; 1988 Sep; 80(13):1016-26. PubMed ID: 3261800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
    Bernhard H; Karbach J; Wölfel T; Busch P; Störkel S; Stöckle M; Wölfel C; Seliger B; Huber C; Meyer zum Büschenfelde KH
    Int J Cancer; 1994 Dec; 59(6):837-42. PubMed ID: 7989126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
    Takahashi T; Irie RF; Nishinaka Y; Hoon DS
    Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells.
    Glazyrin AL; Kan-Mitchell J; Mitchell ML
    Cancer Immunol Immunother; 2003 Mar; 52(3):171-8. PubMed ID: 12649746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo selective expansion of a tumour-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with gene-modified autologous tumour cells.
    Sun Y; Möller P; Berking C; Schlüpen EM; Volkenandt M; Schadendorf D
    Immunology; 1999 Dec; 98(4):535-40. PubMed ID: 10594685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures.
    Hersey P; MacDonald M; Schibeci S; Burns C
    Cancer Immunol Immunother; 1986; 22(1):15-23. PubMed ID: 2423240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 107.